ReviewTheranostics2015
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer.
Review in Theranostics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 441 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
441 citing papers in PubMed, 3 syntheses or guidelines pooled it, 812 citations in OpenAlex.
- A systematic review and meta-analysis of microRNAs in the diagnosis of early diabetic kidney disease.Frontiers in endocrinology · 2025Pooled it
- Panels of circulating microRNAs as potential diagnostic biomarkers for breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2022Pooled it
- The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review.Frontiers in oncology · 2022Pooled it
- Review
- miR-770-5p regulates KDM5B and links its nuclear localization to HER2 signaling in trastuzumab-resistant breast cancer.Molecular and cellular biochemistry · 2026Article
- Curcumol Inhibits the Invasion and Migration of Breast Cancer via miR-206/NCL/ERα36.Phytotherapy research : PTR · 2026Article
- A lateral flow assay strip based on AND logic gate and DNA self-assembly for dual miRNA detection in breast cancer diagnosis.Mikrochimica acta · 2026Article
- miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer Cells.Journal of cellular and molecular medicine · 2026Article
- Split G‑Quadruplex-Programmed Fluorescent Platform for Low Background Signal and Sensitive Nonsmall Cell Lung Cancer-Related MicroRNA Analysis.ACS omega · 2026Article
- Single-cell profiling reveals a novel CAF subpopulation linking stromal heterogeneity to immune suppression in breast cancer subtypes.Journal of translational medicine · 2026Article
- Methylation-mediated regulation of tumor-suppressor function of the miR-379/656 (C14MC) cluster and its clinical utility in hepatocellular carcinoma.BMC cancer · 2026Article
- Praxis-BGM: clustering of omics data using semi-supervised transfer learning for Gaussian mixture models via natural-gradient variational inference.Bioinformatics (Oxford, England) · 2026Article
- Prediction of multicategory miRNA-disease associations based on bidirectional hypergraph attention network and gated convolutional strategy.Journal of computer-aided molecular design · 2026Article
- Review
- Prognostic Value of Cardiac Biomarkers in Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.Cureus · 2026Review
- Ionic Strength Impact on miR-141 Detection by bioFET.ACS omega · 2026Article
- Serum-Based miRNA Panel as Diagnostic Biomarkers for Hepatitis C Virus-Induced Hepatocellular Carcinoma: A Cross-Sectional Study.Health science reports · 2026Article
- Epigenetic regulation in cancer metastasis.Discover oncology · 2026Review
- miR-338-3p promotes radiation recall like dermatitis by suppressing pleiotrophin via the PI3K/Akt/Bcl2 pathway.Molecular biomedicine · 2026Article
- Role of tumor‑infiltrating lymphocytes and miR‑155 in breast cancer: Insights into carcinogenesis and their potential as prognostic biomarkers (Review).Oncology reports · 2026Review
381 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulation of microRNAs (miRNAs) is involved in the initiation and progression of several human cancers, including breast cancer (BC), as strong evidence has been found that miRNAs can act as oncogenes or tumor suppressor genes. This review presents the state of the art on the role of miRNAs in the diagnosis, prognosis, and therapy of BC. Based on the results obtained in the last decade, some miRNAs are emerging as biomarkers of BC for diagnosis (i.e., miR-9, miR-10b, and miR-17-5p), prognosis (i.e., miR-148a and miR-335), and prediction of therapeutic outcomes (i.e., miR-30c, miR-187, and miR-339-5p) and have important roles in the control of BC hallmark functions such as invasion, metastasis, proliferation, resting death, apoptosis, and genomic instability. Other miRNAs are of interest as new, easily accessible, affordable, non-invasive tools for the personalized management of patients with BC because they are circulating in body fluids (e.g., miR-155 and miR-210). In particular, circulating multiple miRNA profiles are showing better diagnostic and prognostic performance as well as better sensitivity than individual miRNAs in BC. New miRNA-based drugs are also promising therapy for BC (e.g., miR-9, miR-21, miR34a, miR145, and miR150), and other miRNAs are showing a fundamental role in modulation of the response to other non-miRNA treatments, being able to increase their efficacy (e.g., miR-21, miR34a, miR195, miR200c, and miR203 in combination with chemotherapy).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.